Sporanox Hart hylki 100 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

sporanox hart hylki 100 mg

janssen-cilag ab - itraconazolum inn - hart hylki - 100 mg

Rimactan Hart hylki 300 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

rimactan hart hylki 300 mg

sandoz gmbh* - rifampicinum inn - hart hylki - 300 mg

Rimactan Hart hylki 150 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

rimactan hart hylki 150 mg

sandoz gmbh* - rifampicinum inn - hart hylki - 150 mg

Risperidone Teva GmbH Stungulyfsstofn og leysir, forðadreifa 50 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

risperidone teva gmbh stungulyfsstofn og leysir, forðadreifa 50 mg

teva gmbh - risperidonum inn - stungulyfsstofn og leysir, forðadreifa - 50 mg

Paclitaxel Actavis Innrennslisþykkni, lausn 6 mg/ml Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

paclitaxel actavis innrennslisþykkni, lausn 6 mg/ml

actavis group ptc ehf. - paclitaxelum inn - innrennslisþykkni, lausn - 6 mg/ml

Marbodin Filmuhúðuð tafla 10 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

marbodin filmuhúðuð tafla 10 mg

stada arzneimittel ag - memantinum hýdróklóríð - filmuhúðuð tafla - 10 mg

Marbodin Filmuhúðuð tafla 20 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

marbodin filmuhúðuð tafla 20 mg

stada arzneimittel ag - memantinum hýdróklóríð - filmuhúðuð tafla - 20 mg

Risperidone Teva GmbH Stungulyfsstofn og leysir, forðadreifa 25 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

risperidone teva gmbh stungulyfsstofn og leysir, forðadreifa 25 mg

teva gmbh - risperidonum inn - stungulyfsstofn og leysir, forðadreifa - 25 mg

Risperidone Teva GmbH Stungulyfsstofn og leysir, forðadreifa 37,5 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

risperidone teva gmbh stungulyfsstofn og leysir, forðadreifa 37,5 mg

teva gmbh - risperidonum inn - stungulyfsstofn og leysir, forðadreifa - 37,5 mg

Vidaza Evrópusambandið - íslenska - EMA (European Medicines Agency)

vidaza

bristol-myers squibb pharma eeig - azasitidín - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - Æxlishemjandi lyf - vidaza is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (hsct) with: intermediate 2 and high-risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss),chronic myelomonocytic leukaemia (cmml) with 10 29 % marrow blasts without myeloproliferative disorder,acute myeloid leukaemia (aml) with 20 30 % blasts and multi-lineage dysplasia, according to world health organisation (who) classification. vidaza is indicated for the treatment of adult patients aged 65 years or older who are not eligible for hsct with aml with >30% marrow blasts according to the who classification.